TGFB1 and glioblastoma: Meanwhile, siTGF‐β could reprogram the immunosuppressive microenvironment of GBM by downregulating TGF‐β expression, ultimately re‐sensitizing chemotherapeutic response and potentiating anti‐GBM immune response.